In this section
@article{Alexandrou:2023:10.3390/cancers15225434,
author = {Alexandrou, G and Mantikas, K-T and Allsopp, R and Yapeter, CA and Jahin, M and Melnick, T and Ali, S and Coombes, RC and Toumazou, C and Shaw, JA and Kalofonou, M},
doi = {10.3390/cancers15225434},
journal = {Cancers},
title = {The evolution of affordable technologies in liquid biopsy diagnostics: the key to clinical implementation},
url = {http://dx.doi.org/10.3390/cancers15225434},
volume = {15},
year = {2023}
}
TY - JOUR
AB - Cancer remains a leading cause of death worldwide, despite many advances in diagnosis and treatment. Precision medicine has been a key area of focus, with research providing insights and progress in helping to lower cancer mortality through better patient stratification for therapies and more precise diagnostic techniques. However, unequal access to cancer care is still a global concern, with many patients having limited access to diagnostic tests and treatment regimens. Noninvasive liquid biopsy (LB) technology can determine tumour-specific molecular alterations in peripheral samples. This allows clinicians to infer knowledge at a DNA or cellular level, which can be used to screen individuals with high cancer risk, personalize treatments, monitor treatment response, and detect metastasis early. As scientific understanding of cancer pathology increases, LB technologies that utilize circulating tumour DNA (ctDNA) and circulating tumour cells (CTCs) have evolved over the course of research. These technologies incorporate tumour-specific markers into molecular testing platforms. For clinical translation and maximum patient benefit at a wider scale, the accuracy, accessibility, and affordability of LB tests need to be prioritized and compared with gold standard methodologies in current use. In this review, we highlight the range of technologies in LB diagnostics and discuss the future prospects of LB through the anticipated evolution of current technologies and the integration of emerging and novel ones. This could potentially allow a more cost-effective model of cancer care to be widely adopted.
AU - Alexandrou,G
AU - Mantikas,K-T
AU - Allsopp,R
AU - Yapeter,CA
AU - Jahin,M
AU - Melnick,T
AU - Ali,S
AU - Coombes,RC
AU - Toumazou,C
AU - Shaw,JA
AU - Kalofonou,M
DO - 10.3390/cancers15225434
PY - 2023///
SN - 2072-6694
TI - The evolution of affordable technologies in liquid biopsy diagnostics: the key to clinical implementation
T2 - Cancers
UR - http://dx.doi.org/10.3390/cancers15225434
UR - https://www.ncbi.nlm.nih.gov/pubmed/38001698
UR - https://www.mdpi.com/2072-6694/15/22/5434
UR - http://hdl.handle.net/10044/1/108254
VL - 15
ER -
Centre for Bio-Inspired Technology
Imperial College London
Bessemer Building
South Kensington
SW7 2AZ, UK
Tel: +44 (0)207 594 0701
Fax: +44 (0)207 594 0704
E-mail: bioinspired@imperial.ac.uk